Drug Trial Radar · NCT06544499
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
69
Planned (sponsor's estimate)
Start
Oct 18, 2024
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext
Conditions
- Primary Immune Thrombocytopenia (ITP)
Interventions
Efgartigimod IVBiological
Intravenous infusion of efgartigimod
Placebo IVOther
Intravenous infusion of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Extent of disease control, defined as the number of cumulative weeks during the 24-week Double-Blinded Treatment Period with platelet counts of at least 50 × 10^9/LTime frame: Up to 24 weeks
Locations
94 sites in 17 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital Scottsdale
Phoenix, Arizona · Recruiting
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Sharp Memorial Hospital
Oceanside, California · Recruiting
University of Colorado Hospital
Aurora, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
The University of Chicago Medicine
Chicago, Illinois · Recruiting
The University of Iowa Hospitals & Clinics
Iowa City, Iowa · Recruiting
Tulane University
New Orleans, Louisiana · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Regional Cancer Care Associates, LLC (RCCA)
Little Silver, New Jersey · Recruiting
Clinical Research Alliance Inc.
Westbury, New York · Terminated
Duke University Medical Center
Durham, North Carolina · Recruiting
Brody School of Medicine at East Carolina University
Greenville, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Ohio State University Hospital East
Columbus, Ohio · Recruiting
INTEGRIS Cancer Institute of Oklahoma
Oklahoma City, Oklahoma · Recruiting
Allgemeines Krankenhaus der Stadt Linz
Linz, Austria · Recruiting
Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria · Recruiting
Klinikum Kreuzschwestern Wels
Wels, Austria · Recruiting
Acibadem City clinic Tokuda hospital
Sofia, Bulgaria · Recruiting
UMHAT Aleksandrovska
Sofia, Bulgaria · Recruiting
University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski
Sofia, Bulgaria · Recruiting
National Specialized Hospital for Active Treatment of Hematology Diseases
Sofia, Bulgaria · Recruiting
UMHAT SofiaMed
Sofia, Bulgaria · Recruiting
University Hospital Prof. Dr. Stoyan Kirkovich AD
Stara Zagora, Bulgaria · Recruiting
Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University
Beijing, China · Recruiting
Peking University Third Hospital
Beijing, China · Recruiting
The First Affiliated Hospital Of Bengbu Medical College
Bengbu, China · Recruiting
The Affiliated Hospital of Chengde Medical University
Chengde, China · Recruiting
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China · Recruiting
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
Huai'an, China · Recruiting
Huizhou Central People's Hospital
Huizhou, China · Recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China · Recruiting
Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)
Wuhan, China · Recruiting
Wuxi People's Hospital (Wuxi No.1 People's Hospital)
Wuxi, China · Recruiting
Affiliated Hospital of Jiangsu University
Zhenjiang, China · Recruiting
University Hospital Center Zagreb
Zagreb, Croatia · Recruiting
Fakultni Nemocnice Ostrava
Ostrava, Czechia · Recruiting
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.